<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331006</url>
  </required_header>
  <id_info>
    <org_study_id>374</org_study_id>
    <secondary_id>U01HL072268</secondary_id>
    <secondary_id>U01HL072274</secondary_id>
    <secondary_id>U01HL072290</secondary_id>
    <secondary_id>U01HL072033</secondary_id>
    <secondary_id>U01HL072291</secondary_id>
    <secondary_id>U01HL072248</secondary_id>
    <secondary_id>U01HL072355</secondary_id>
    <secondary_id>U01HL072283</secondary_id>
    <secondary_id>U01HL072346</secondary_id>
    <secondary_id>U01HL072331</secondary_id>
    <nct_id>NCT00331006</nct_id>
  </id_info>
  <brief_title>Rituximab to Treat Severe Hemophilia A</brief_title>
  <acronym>RICH</acronym>
  <official_title>Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (A TMH CTN Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemophilia A is a serious blood clotting disorder caused by a lack of factor VIII, a
      specialized protein needed for normal blood clotting to occur. Individuals with this disease
      may experience spontaneous bleeding, pain and swelling in their joints due to excess
      bleeding, and bruising. A common treatment for severe hemophilia A is to intravenously
      replace the deficient blood clotting factor; however, some individuals may develop antibodies
      to this replacement factor. This study will evaluate the effectiveness of rituximab at
      reducing the antibodies that develop in response to the replacement factor in individuals
      with severe hemophilia A.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemophilia A is a hereditary blood clotting disorder. It is caused by a deficiency or
      abnormality of the blood clotting protein factor VIII. Individuals with hemophilia A are
      unable to form blood clots to stop bleeding and are at risk for experiencing serious and
      life-threatening bleeding episodes. The most common treatment for this disease is intravenous
      replacement of factor VIII. However, between 30 to 40% of individuals eventually develop
      inhibitors, or antibodies, to the replacement factor. In these individuals, the immune system
      recognizes the replacement factor as foreign and attacks it, thereby countering any potential
      benefits of the treatment. Some individuals with severe hemophilia A may undergo immune
      tolerance therapy (ITT), in which they receive replacement factor on a regular basis as a way
      for the body to adjust to the factor and stop inhibitor production. This treatment, however,
      is not always effective for everyone. Preliminary research has shown that rituximab, a
      medication used to treat non-Hodgkin's lymphoma, may be successful in suppressing or
      eliminating the inhibitors that develop. The purpose of this study is to evaluate the
      effectiveness of rituximab at lowering the levels of factor VIII inhibitors in individuals
      with severe hemophilia A.

      This study will enroll individuals with severe hemophilia A. At study entry, participants
      will receive one intravenous dose of factor VIII. Inhibitor levels will be measured with a
      blood test 5 to 7 days following this procedure. If peak inhibitor level is above 5 Bethesda
      units (BU)/mL, 5 to 9 days later participants will begin receiving rituximab intravenously
      once a week for 4 weeks. Blood will be collected at each visit for laboratory testing. Two
      weeks following the last rituximab treatment, participants will have blood drawn for
      inhibitor testing; this testing will occur every 4 weeks through Week 22. If the
      participant's inhibitor level falls below 5 BU/mL, participants will receive a repeat dose of
      factor VIII, and blood will be drawn 5 to 7 days later for inhibitor testing. Follow-up
      visits will occur at Weeks 36, 52, and 100, and will include a physical examination, blood
      collection, and monitoring of bleeding events and infections. Telephone interviews will be
      conduced at Weeks 64, 76, and 88 to monitor bleeding events and infections.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With Major Response, i.e. Inhibitor Level Falls to Less Than 5 BU/mL Between Weeks 6 to 22 and Remains Below 5 BU/mL at 5-7 Days Following Re-challenge With FVIII</measure>
    <time_frame>Measured within approximately 22 weeks</time_frame>
    <description>Presence or absence of a major response in each participant. Major response is defined as occurring when inhibitor level falls to less than 5 BU/mL between Weeks 6 to 22 and remains below 5 BU/mL at 5-7 days following re-challenge with FVIII</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With at Least Minor Response, i.e. Inhibitor Level Falls to &lt;5 BU/mL Between Weeks 6-22 and Either Remains &lt;5 BU/mL 5-7 Days Following FVIII Rechallenge or Titer Following FVIII Rechallenge is 5-10 BU/mL &amp; &lt;50% of Original Peak</measure>
    <time_frame>Measured within approximately 22 weeks</time_frame>
    <description>Presence or absence of at least a minor response in each participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Inhibitor Titer on Challenge With Factor VIII From Baseline Challenge to Post-treatment Challenge</measure>
    <time_frame>Measured within approximately 22 weeks</time_frame>
    <description>percent change=100%*(A-B)/B where A=inhibitor titer measured within 5-7 days following FVIII rechallenge and B=inhibitor titer measured within 5-14 days following baseline FVIII challenge. A FVIII rechallenge was performed within 10-18 days of the first monthly study visit in which an inhibitor titer result &lt;5 BU/mL was obtained beginning 2 weeks and continuing through 18 weeks following the last rituximab infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Bleeding Events Per Subject Meeting the Criteria of a Serious Adverse Event</measure>
    <time_frame>Measured through Week 100</time_frame>
    <description>Median number of bleeding events per subject meeting the criteria of a serious adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Bleeding Events Per Subject Not Meeting the Criteria of a Serious Adverse Event</measure>
    <time_frame>Measured through Week 100</time_frame>
    <description>Median Number of Bleeding Events Per Subject Not Meeting the Criteria of a Serious Adverse Event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Serious Adverse Events Per Subject Other Than Bleeding Events</measure>
    <time_frame>Measured through Week 100</time_frame>
    <description>Median Number of Serious Adverse Events Per Subject Other Than Bleeding Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Adverse Events Per Subject That Were Not Bleeding Events and Did Not Meet the Criteria of a Serious Adverse Event</measure>
    <time_frame>Measured through Week 100</time_frame>
    <description>Median Number of Adverse Events Per Subject That Were Not Bleeding Events and Did Not Meet the Criteria of a Serious Adverse Event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Rituximab Infusions in Which a Reaction to the Infusion Was Reported</measure>
    <time_frame>Measured at Week 1 through Week 4</time_frame>
    <description>Proportion of rituximab infusions in which a reaction to the infusion was reported</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab administered at a dose of 375 mg/m2 by slow intravenous infusion once per week for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe congenital hemophilia A

          -  Documented historical inhibitor titer to factor VIII of at least 5 BU/mL

          -  Inhibitor level greater than or equal to 5 BU/mL 5 to 14 days after initial factor
             VIII exposure during screening

        Exclusion Criteria:

          -  Known hypersensitivities or allergies to murine and/or humanized antibodies

          -  Currently participating in investigational hemophilia studies

          -  HIV infected

          -  Any immunodeficiency disorder

          -  Liver disease and serum ALT or AST is greater than three times the upper limit of
             normal, albumin is less than 2.5g/dl, and/or INR is greater than 1.7

          -  Received interferon or other immunomodulatory drugs, such as steroids or cytotoxic
             therapy in the 30 days prior to study entry

          -  History of cardiac arrhythmias, any active febrile illness, kidney insufficiency, or
             pulmonary infiltrates

          -  Has previously received rituximab treatment

          -  Currently undergoing immune tolerance therapy

          -  Evidence of Hepatitis B (HBV) infection, defined as one of the following:

               -  HBsAg positive

               -  HBsAg negative, HBsAb negative, HBcAb positive, and HBV DNA positive

          -  Participants with a high responding inhibitor (at least 5 BU/mL) first detected fewer
             than 12 months prior to study entry, unless the participant has failed immune
             tolerance therapy, defined as one of the following:

               1. Failure to fulfill the criteria for full or partial success within 33 months, as
                  defined by a factor VIII recovery greater than or equal to 66% of expected and
                  half-life greater than or equal to 6 hours measured after a 72-hour
                  treatment-free washout period

               2. Failure to achieve greater than 20% reduction in inhibitor titer during each
                  interim non-overlapping 6-month period of ITT in the absence of documented
                  infection, with 9 months as the minimum treatment period and 33 months as the
                  maximum possible duration of unsuccessful ITT

               3. Withdrawal from ITT for any other reason

          -  Routinely receive factor VIII concentrate for the treatment of both major and minor
             bleeding events

          -  Has received factor VIII concentrate in the 7 days prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan F. Assmann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NERI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cindy Leissinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Gill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood Center of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith McCrae, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Cleveland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ellis Neufeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cassandra Josephson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Healthcare of Atlanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nigel Key, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Sexauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janna Journeycake, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leslie Raffini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret Ragni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hemophilia Center of Western Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard Valentino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diane Nugent, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children’s Hospital of Orange County</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcella Torres, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cook Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC at Chapel Hill Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemophilia Center of Western Pennsylvania</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Center for Bleeding Disorders</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2006</study_first_submitted>
  <study_first_submitted_qc>May 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2006</study_first_posted>
  <results_first_submitted>January 7, 2013</results_first_submitted>
  <results_first_submitted_qc>June 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2013</results_first_posted>
  <last_update_submitted>June 7, 2013</last_update_submitted>
  <last_update_submitted_qc>June 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Coagulation Factor Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Factor VIII</mesh_term>
    <mesh_term>Blood Coagulation Factor Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at clinical sites and Hemophilia Treatment Centers participating in the study. The recruitment period began in August 2006 and continued through November 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rituximab</title>
          <description>Rituximab administered at a dose of 375 mg/m^2 by slow intravenous infusion once per week for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16">subjects eligible for the treatment phase if inhibitor titer following Factor VIII was at least 5 BU</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>enrollment halted</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible for treatment phase</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up Phase I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who began the screening phase</population>
      <group_list>
        <group group_id="B1">
          <title>Rituximab</title>
          <description>Rituximab administered at a dose of 375 mg/m^2 by slow intravenous infusion once per week for 4 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.85" spread="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With Major Response, i.e. Inhibitor Level Falls to Less Than 5 BU/mL Between Weeks 6 to 22 and Remains Below 5 BU/mL at 5-7 Days Following Re-challenge With FVIII</title>
        <description>Presence or absence of a major response in each participant. Major response is defined as occurring when inhibitor level falls to less than 5 BU/mL between Weeks 6 to 22 and remains below 5 BU/mL at 5-7 days following re-challenge with FVIII</description>
        <time_frame>Measured within approximately 22 weeks</time_frame>
        <population>All participants who received at least one dose of rituximab</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>Rituximab administered at a dose of 375 mg/m^2 by slow intravenous infusion once per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Major Response, i.e. Inhibitor Level Falls to Less Than 5 BU/mL Between Weeks 6 to 22 and Remains Below 5 BU/mL at 5-7 Days Following Re-challenge With FVIII</title>
          <description>Presence or absence of a major response in each participant. Major response is defined as occurring when inhibitor level falls to less than 5 BU/mL between Weeks 6 to 22 and remains below 5 BU/mL at 5-7 days following re-challenge with FVIII</description>
          <population>All participants who received at least one dose of rituximab</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".1875" lower_limit="0.053" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the proportion of participants in which the inhibitor level falls to less than 5 BU/mL between weeks 6 to 22 and remains below 5 BU/mL at 5-7 days following re-challenge with factor VIII is no more than 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <p_value_desc>the a priori p-value was 0.05 for statistical significance</p_value_desc>
            <method>Exact Binomial</method>
            <param_type>Proportion</param_type>
            <param_value>.1875</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>.053</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With at Least Minor Response, i.e. Inhibitor Level Falls to &lt;5 BU/mL Between Weeks 6-22 and Either Remains &lt;5 BU/mL 5-7 Days Following FVIII Rechallenge or Titer Following FVIII Rechallenge is 5-10 BU/mL &amp; &lt;50% of Original Peak</title>
        <description>Presence or absence of at least a minor response in each participant</description>
        <time_frame>Measured within approximately 22 weeks</time_frame>
        <population>All participants who received at least one dose of rituximab</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>Rituximab administered at a dose of 375 mg/m^2 by slow intravenous infusion once per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With at Least Minor Response, i.e. Inhibitor Level Falls to &lt;5 BU/mL Between Weeks 6-22 and Either Remains &lt;5 BU/mL 5-7 Days Following FVIII Rechallenge or Titer Following FVIII Rechallenge is 5-10 BU/mL &amp; &lt;50% of Original Peak</title>
          <description>Presence or absence of at least a minor response in each participant</description>
          <population>All participants who received at least one dose of rituximab</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.073" upper_limit="0.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>No hypothesis about the value of this proportion was specified in the study design</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Proportion</param_type>
            <param_value>.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.073</ci_lower_limit>
            <ci_upper_limit>0.524</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Inhibitor Titer on Challenge With Factor VIII From Baseline Challenge to Post-treatment Challenge</title>
        <description>percent change=100%*(A-B)/B where A=inhibitor titer measured within 5-7 days following FVIII rechallenge and B=inhibitor titer measured within 5-14 days following baseline FVIII challenge. A FVIII rechallenge was performed within 10-18 days of the first monthly study visit in which an inhibitor titer result &lt;5 BU/mL was obtained beginning 2 weeks and continuing through 18 weeks following the last rituximab infusion.</description>
        <time_frame>Measured within approximately 22 weeks</time_frame>
        <population>All subjects who received a post-treatment rechallenge and had at least a minor response.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>Rituximab administered at a dose of 375 mg/m^2 by slow intravenous infusion once per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Inhibitor Titer on Challenge With Factor VIII From Baseline Challenge to Post-treatment Challenge</title>
          <description>percent change=100%*(A-B)/B where A=inhibitor titer measured within 5-7 days following FVIII rechallenge and B=inhibitor titer measured within 5-14 days following baseline FVIII challenge. A FVIII rechallenge was performed within 10-18 days of the first monthly study visit in which an inhibitor titer result &lt;5 BU/mL was obtained beginning 2 weeks and continuing through 18 weeks following the last rituximab infusion.</description>
          <population>All subjects who received a post-treatment rechallenge and had at least a minor response.</population>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.31" lower_limit="-77.11" upper_limit="-44.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Bleeding Events Per Subject Meeting the Criteria of a Serious Adverse Event</title>
        <description>Median number of bleeding events per subject meeting the criteria of a serious adverse event</description>
        <time_frame>Measured through Week 100</time_frame>
        <population>Data on bleeding events were collected at every study visit for all study participants. Data for this outcome was collected through the particpants end of study or Week 100, whichever came first, and is restricted to the 16 subjects who received at least one dose of rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>Rituximab administered at a dose of 375 mg/m^2 by slow intravenous infusion once per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Bleeding Events Per Subject Meeting the Criteria of a Serious Adverse Event</title>
          <description>Median number of bleeding events per subject meeting the criteria of a serious adverse event</description>
          <population>Data on bleeding events were collected at every study visit for all study participants. Data for this outcome was collected through the particpants end of study or Week 100, whichever came first, and is restricted to the 16 subjects who received at least one dose of rituximab.</population>
          <units>participants</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Bleeding Events Per Subject Not Meeting the Criteria of a Serious Adverse Event</title>
        <description>Median Number of Bleeding Events Per Subject Not Meeting the Criteria of a Serious Adverse Event</description>
        <time_frame>Measured through Week 100</time_frame>
        <population>Data on bleeding events were collected at every study visit for all study participants. Data for this outcome was collected through the particpants end of study or Week 100, whichever came first, and is restricted to the 16 subjects who received at least one dose of rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>Rituximab administered at a dose of 375 mg/m^2 by slow intravenous infusion once per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Bleeding Events Per Subject Not Meeting the Criteria of a Serious Adverse Event</title>
          <description>Median Number of Bleeding Events Per Subject Not Meeting the Criteria of a Serious Adverse Event</description>
          <population>Data on bleeding events were collected at every study visit for all study participants. Data for this outcome was collected through the particpants end of study or Week 100, whichever came first, and is restricted to the 16 subjects who received at least one dose of rituximab.</population>
          <units>participants</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="11" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Serious Adverse Events Per Subject Other Than Bleeding Events</title>
        <description>Median Number of Serious Adverse Events Per Subject Other Than Bleeding Events</description>
        <time_frame>Measured through Week 100</time_frame>
        <population>Data on bleeding events were collected at every study visit for all study participants. Data for this outcome was collected through the particpants end of study or Week 100, whichever came first, and is restricted to the 16 subjects who received at least one dose of rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>Rituximab administered at a dose of 375 mg/m^2 by slow intravenous infusion once per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Serious Adverse Events Per Subject Other Than Bleeding Events</title>
          <description>Median Number of Serious Adverse Events Per Subject Other Than Bleeding Events</description>
          <population>Data on bleeding events were collected at every study visit for all study participants. Data for this outcome was collected through the particpants end of study or Week 100, whichever came first, and is restricted to the 16 subjects who received at least one dose of rituximab.</population>
          <units>participants</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Adverse Events Per Subject That Were Not Bleeding Events and Did Not Meet the Criteria of a Serious Adverse Event</title>
        <description>Median Number of Adverse Events Per Subject That Were Not Bleeding Events and Did Not Meet the Criteria of a Serious Adverse Event</description>
        <time_frame>Measured through Week 100</time_frame>
        <population>Data on bleeding events were collected at every study visit for all study participants. Data for this outcome was collected through the particpants end of study or Week 100, whichever came first, and is restricted to the 16 subjects who received at least one dose of rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>Rituximab administered at a dose of 375 mg/m^2 by slow intravenous infusion once per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Adverse Events Per Subject That Were Not Bleeding Events and Did Not Meet the Criteria of a Serious Adverse Event</title>
          <description>Median Number of Adverse Events Per Subject That Were Not Bleeding Events and Did Not Meet the Criteria of a Serious Adverse Event</description>
          <population>Data on bleeding events were collected at every study visit for all study participants. Data for this outcome was collected through the particpants end of study or Week 100, whichever came first, and is restricted to the 16 subjects who received at least one dose of rituximab.</population>
          <units>participants</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Rituximab Infusions in Which a Reaction to the Infusion Was Reported</title>
        <description>Proportion of rituximab infusions in which a reaction to the infusion was reported</description>
        <time_frame>Measured at Week 1 through Week 4</time_frame>
        <population>All rituximab infusions given to study participants</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>Rituximab administered at a dose of 375 mg/m^2 by slow intravenous infusion once per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Rituximab Infusions in Which a Reaction to the Infusion Was Reported</title>
          <description>Proportion of rituximab infusions in which a reaction to the infusion was reported</description>
          <population>All rituximab infusions given to study participants</population>
          <units>proportion of rituximab infusions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>rituximab infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.05" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through week 100</time_frame>
      <desc>Restricted to the 16 subjects who received at least one dose of rituximab.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rituximab</title>
          <description>Rituximab administered at a dose of 375 mg/m^2 by slow intravenous infusion once per week for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Modified CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Meeting Serious Adverse Event Criteria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Meeting Serious Adverse Event Criteria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pulmonary/upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Viral meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Zoster infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bleeding and/or hematoma due to injury</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bleeding and/or hematoma due to procedure complication</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hematoma due to injury</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hematoma due to procedure complication</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint and other bleeding due to injury</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint bleeding due to injury</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint bleeding due to procedure complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding and/or hematoma - spontaneous</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bone fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint and other bleeding - spontaneous</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint bleeding - spontaneous</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Subdural hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Port placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Port removal and replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Synovectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Meeting serious adverse event criteria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Splenic hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Modified CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Enlarged lymph nodes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased blood lymphocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Increased blood monocytes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>White blood cell decrease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Pink eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bleeding - spontaneous</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bleed and/or hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased ALT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold sore</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Group A strep</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Septic polyarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bleed and/or hematoma due to injury</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bleeding due to injury</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bleeding due to procedure complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint bleeding due to injury</sub_title>
                <counts group_id="E1" events="31" subjects_affected="11" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint pain due to injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>vaccination site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hematoma due to injury</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hematoma due to procedure complication</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint bleeding, spontaneous</sub_title>
                <counts group_id="E1" events="262" subjects_affected="15" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint pain, spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Muscle pain, spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bleed and/or hematoma - spontaneous</sub_title>
                <counts group_id="E1" events="26" subjects_affected="10" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bleeding - spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hematoma - spontaneous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bells palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bleeding - spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Intolerance to light</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding - spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bleeding - spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Elevated carbon dioxide in the blood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Runny nose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bleed and/or hematoma - spontaneous</sub_title>
                <counts group_id="E1" events="20" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hematoma - spontaneous</sub_title>
                <counts group_id="E1" events="24" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bleeding - spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>High blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Low blood pressure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter donated Factor VIII and Genentech donated rituximab for the study. Both Baxter and Genentech can review results communications prior to public release for a period of time less than or equal to 60 days from the time submitted to them for review. These companies cannot require changes to the communication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated before reaching its target sample size of 50 subjects due to low enrollment rates. Therefore, confidence intervals for proportions are wide.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Susan F. Assmann, PhD</name_or_title>
      <organization>New England Research Institutes, Inc.</organization>
      <phone>617-972-3048</phone>
      <email>sassmann@neriscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

